[go: up one dir, main page]

BR0010843A - Antagonistas de receptores de il-8 - Google Patents

Antagonistas de receptores de il-8

Info

Publication number
BR0010843A
BR0010843A BR0010843-0A BR0010843A BR0010843A BR 0010843 A BR0010843 A BR 0010843A BR 0010843 A BR0010843 A BR 0010843A BR 0010843 A BR0010843 A BR 0010843A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
phenylureas
chemokine
interleukin
treatment
Prior art date
Application number
BR0010843-0A
Other languages
English (en)
Inventor
Michael R Palovich
Katherine L Widdowson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0010843A publication Critical patent/BR0010843A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"ANTAGONISTAS DE RECEPTORES DE IL-8". Esta invenção refere-se ao uso inovador de fenil-uréias no tratamento de estados doentios mediados pela quimiocina, Interleucina-8 (IL-8).
BR0010843-0A 1999-05-28 2000-05-26 Antagonistas de receptores de il-8 BR0010843A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13671799P 1999-05-28 1999-05-28
PCT/US2000/014661 WO2000072845A1 (en) 1999-05-28 2000-05-26 Il-8 receptor antagonists

Publications (1)

Publication Number Publication Date
BR0010843A true BR0010843A (pt) 2002-02-19

Family

ID=22474057

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010843-0A BR0010843A (pt) 1999-05-28 2000-05-26 Antagonistas de receptores de il-8

Country Status (27)

Country Link
US (1) US6566387B1 (pt)
EP (1) EP1180028B1 (pt)
JP (1) JP2003500447A (pt)
KR (1) KR20020010674A (pt)
CN (1) CN1353606A (pt)
AR (1) AR029637A1 (pt)
AT (1) ATE352299T1 (pt)
AU (1) AU766082B2 (pt)
BR (1) BR0010843A (pt)
CA (1) CA2375683A1 (pt)
CO (1) CO5170514A1 (pt)
CZ (1) CZ20014247A3 (pt)
DE (1) DE60033145T2 (pt)
DK (1) DK1180028T3 (pt)
ES (1) ES2280217T3 (pt)
HK (1) HK1045257A1 (pt)
HU (1) HUP0201300A3 (pt)
IL (1) IL146046A0 (pt)
MX (1) MXPA01012268A (pt)
NO (1) NO20015775D0 (pt)
NZ (1) NZ514729A (pt)
PL (1) PL351946A1 (pt)
PT (1) PT1180028E (pt)
SI (1) SI1180028T1 (pt)
TR (1) TR200103448T2 (pt)
WO (1) WO2000072845A1 (pt)
ZA (1) ZA200109628B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495569B1 (en) 2001-04-19 2002-12-17 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
AR041834A1 (es) * 2002-10-29 2005-06-01 Smithkline Beecham Corp Compuesto de difenilurea sustituido con sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
WO2004045518A2 (en) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
JP2008517054A (ja) * 2004-10-20 2008-05-22 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
WO2007124423A2 (en) * 2006-04-21 2007-11-01 Smithkline Beecham Corporation Il-8 receptor antagonists
CL2007001142A1 (es) * 2006-04-21 2008-01-25 Smithkline Beecham Corp Compuestos derivados de sulfona, antagonistas del receptor il-8; procedimiento de preparacion;compuestos intermediarios;composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de asma, enfermedad pulmonar obstructiva cronica, dermatitis, psoriasis, alzheimer, aterosclerosis, osteoporosis.
CL2007001829A1 (es) * 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516621A (ja) * 1996-08-15 2000-12-12 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８レセプターアンタゴニスト
JP2001527519A (ja) * 1996-08-15 2001-12-25 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８レセプターアンタゴニスト
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
WO1998006398A1 (en) * 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
WO1998006701A1 (en) * 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
AU726858B2 (en) 1997-01-23 2000-11-23 Smithkline Beecham Corporation IL-8 receptor antagonists
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8

Also Published As

Publication number Publication date
HUP0201300A2 (hu) 2002-12-28
DK1180028T3 (da) 2007-05-21
US6566387B1 (en) 2003-05-20
EP1180028A1 (en) 2002-02-20
AR029637A1 (es) 2003-07-10
CO5170514A1 (es) 2002-06-27
CN1353606A (zh) 2002-06-12
KR20020010674A (ko) 2002-02-04
NZ514729A (en) 2003-11-28
ZA200109628B (en) 2002-11-22
EP1180028B1 (en) 2007-01-24
CA2375683A1 (en) 2000-12-07
NO20015775L (no) 2001-11-27
ES2280217T3 (es) 2007-09-16
DE60033145D1 (de) 2007-03-15
IL146046A0 (en) 2002-07-25
JP2003500447A (ja) 2003-01-07
HUP0201300A3 (en) 2003-02-28
PL351946A1 (en) 2003-07-14
WO2000072845A1 (en) 2000-12-07
DE60033145T2 (de) 2007-10-31
AU5169100A (en) 2000-12-18
CZ20014247A3 (cs) 2002-05-15
TR200103448T2 (tr) 2002-06-21
SI1180028T1 (sl) 2007-06-30
HK1045257A1 (zh) 2002-11-22
PT1180028E (pt) 2007-04-30
ATE352299T1 (de) 2007-02-15
NO20015775D0 (no) 2001-11-27
EP1180028A4 (en) 2002-10-23
AU766082B2 (en) 2003-10-09
MXPA01012268A (es) 2002-07-30

Similar Documents

Publication Publication Date Title
BR9612779A (pt) Antagonistas ao receptor de il-8
BR0110968A (pt) Antagonistas dos receptores de il-8
BR9916159A (pt) Sulfonamidas de hidróxi-difenil-uréia comoantagonistas dos receptores de il-8
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
PT1047781E (pt) Receptores de il-18
EP1357909A4 (en) ANTAGONISTS OF IL-8 RECEPTORS
BR0010843A (pt) Antagonistas de receptores de il-8
BR0108866A (pt) Antagonistas de receptor de il-8
WO2001068568A3 (en) Il-8 receptor antagonists
BR0010863A (pt) Antagonistas de receptores de il-8
WO2001068569A3 (en) Il-8 receptor antagonists
AP1548A (en) Il-8 Receptor Antagonists.
NZ514696A (en) IL-8 receptor antagonists
WO2000072800A3 (en) Il-8 receptor antagonists
WO2001076530A3 (en) Il-8 receptor antagonists
WO2001064165A3 (en) Il-8 receptor antagonists
AP2002002606A0 (en) INTERLEUKIN 8 RECEPTOR ANTAGONISTS
WO2001068033A3 (en) Il-8 receptor antagonists
MXPA03000500A (es) Uso de antagonistas del receptor de isoleucina 8 en el tratamiento de infecciones por virus.
AR002996A1 (es) Isoxazolinas mejoradas antagonistas del receptore de fibrinogeno.
HK1044475A1 (zh) Il-8受体拮抗剂
BR0010985A (pt) Antagonistas de receptor de il-8
BR9815951A (pt) Antagonistas do receptor de il-8
AP9801315A0 (en) IL-8 receptor antagonists.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.